期刊文献+

服用他克莫司的肾移植患者ABCB1基因多态性与术后感染的相关性 被引量:7

Correlation between ABCB1 polymorphism and postoperative infection in renal transplant patients using tacrolimus
原文传递
导出
摘要 目的:观察服用他克莫司(Tacrolimus)的肾移植受者ABCB1基因多态性对于术后感染发生的影响。方法:选取行肾移植手术并服用他克莫司的患者90例,根据术后是否存在感染分为感染组和对照组,检测所有患者的ABCB1基因型3435C>T,1236C>T和2677G>A/T。采用χ2检验,方差分析和独立样本T检验的方法对患者的基本临床资料进行检验。采用卡方检验比较感染组和未感染组的基因多态性频率分布差异。结果:患者C1236T,C3435T,G2677A/T等位基因频率,均符合Hardy-Weinberg平衡。感染组和非感染组患者的年龄,性别,体质量,临床诊断,吗替麦考酚酯(Mycophenolate Mofetil)的用量均没有显著性差异。2组患者的平均血药谷浓度在一年内均无统计学差异。C1236T单核苷酸多态性对肾移植术后感染发生的影响具有统计学意义(P=0.034)。G2677A/T突变的发生对肾移植术后感染发生的影响具有统计学意义(P=0.010)。结论:ABCB1基因多态性中,仅C1236T的SNP多态性与G2677A/T的突变对肾移植术后感染发生的影响具有统计学意义。 OBJECTIVE To investigate effects of ABCB1 polymorphism on tacrolimus related infection. METItODS Ninety renal transplant patients who used tacrolimus were divided into infection group and control group. ABCB1 of C1236T, C3435T and G2677A/T polymorphism were genotyped. (2 test, one-way ANOVA test and independent sample T test were used to ana- lyze basic clinical data of patients. (2 test was used to compare ABCB1 polymorphism discrepancy between infection group and control group. RESULTS Allele frequencies of C1236T, C3435T, G2677A/T were all fitted Hardy-Weinberg equilibrium. No difference was found in age, weight, sex, clinical diagnosis or dosage of mycophenolate mofetil between infection group and control group. There was no difference in average blood trough concentration between two groups in one year. C1236T mono- nucleotide polymorphism had significant effects on infection after renal transplantation (P = 0. 034). Mutation of G2677A/T had statistical significance on infection after operation (P = 0. 010). CONCLUSION Polymorphism of C1236T and mutation of G2677A/T both show significant effects on tacrolimus-related infection after renal transplantation.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2016年第4期305-309,共5页 Chinese Journal of Hospital Pharmacy
基金 南京市科委科技发展项目(编号:2014YX001)
关键词 他克莫司 ABCB1 肾移植 感染 tacrolimus ABCBI renal transplantation infection
  • 相关文献

参考文献22

  • 1Huai Q,Kim HY,Liu Y, et al. Crystal structure of calci neurin-eyclophilin cyclosporin shows common hut distinct rec- ognition of irmnunophilin--drug complexes[J]. Proc Natl Acad Sci USA, 2002,99 (19) : 12037-12042.
  • 2Kino T, Hatanaka H, Miyata S, et al. FK--506, a novel im munosuppressant isolated from a Streptomyces. II. Irmnuno- suppressive effect of FK-506 in vitro [J]. J Antibiot, 1987,40 (9) : I256-1265.
  • 3Katari SR, Magnone M, Shapiro R, et al. Tacrolimus neph rotoxicity after renal transplantation[J]. Transplant Proe 1997,29(1-2) :311.
  • 4Yadav DK, Gera DN, Gumber MR, et al. Tacrolimus-in duced severe cholestasis complicating renal transplantation[J]. Ren Fail,2013,35(5) :735-737.
  • 5Fishman JA. Infection in solid-organ transplant recipients[J]. N Engl J Med,2007,357(25) :2601-2614.
  • 6Gijsen V, Mital S, van Schaik RH, et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients[J]. J Heart Lung Transplant, 2011,30(12) : 1352-1359.
  • 7朱琳,宋洪涛,王庆华,吴卫真,杨顺良,谭建明.CYP3A4*18B和CYP3A5*3基因多态性对肾移植患者他克莫司剂量及浓度的影响[J].药学学报,2012,47(7):878-883. 被引量:46
  • 8Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycopro tein transports cyelosporin A and FK506[J]. J Biol Chem, 1993,268 (9) : 6077-6080.
  • 9Chaudhary PM, Mechetner EB, Roninson lB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes[J]. Blood, 1992, 80 ( 11 ) : 2735 2739.
  • 10Capron A, Mourad M, De Meyer M, etal. CYP3A5 andAB- CB1 polymorphisms influence tacrolimus concentrations in pe- ripheral blood mononuelear cells after renal transplantation [J]. Pharrnacogenomics, 2010,11 (5) : 703-714.

二级参考文献50

  • 1Rohatagi S,Hochhaus G,Mollmann H,et al.Pharmacokinetics interaction between endogenous cortisol and exogenous corticosteroids[J].Pharmazie 1995,50(9):610-613.
  • 2Boudinot FD,Jusko WJ.Plasma protein binding interaction of prednisone and prednisolone[J].J Steroid Biochem 1984,21 (3):337-339.
  • 3Lewis GP,Jusko WJ,Graves L,et al.Prednisone side-effects and serum-protein levels:a collaborative study[J].Lancet 1971,Ⅱ (7728):778-780.
  • 4Diederich S,Eigendorff E,Burkhardt P,et al.11 β-hydroxysteroid dehydrogenase types 1 and 2:an important pharmacokinetic determinant for the activity of synthetic mineralo-and glucocorticoids[J].J Clin Endocrinol Metab 2002,87 (12):5695-701.
  • 5Ebling WF,Milsap RL,Szefler SJ,et al.6αmethylprednisolone and 6αmethylprednisolone plasma protein binding in humans and rabbits[J].J Pharm Sci 1986,75(8):760-763.
  • 6Mollmann H,Rohdewald P,Barth J,et al.pharmacokinetics and dose linearity testing of methylprednisolone phosphate[J].Biopharm Drug Dispos,1989,10(5):453-464.
  • 7Mollmann H,Hochhaus G,Rohatagi S,et al.pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone[J].Pharm Res 1995,12(7):1096-1100.
  • 8shashank R,Jurgen B,Helmut M,et al.Pharmacokinetics of methylprednisolone and prednisolone after single and multi-oral administration[J].J Clin Pharmacol 1997,37:916-925.
  • 9Kawai S,Ichikawa Y,Homma M.Differences in metabolic properties among cortisol,prednisolone,and dexamethasone in liver and renal disease:accelerated metabolism of dexamethasone in renal failure[J].J Clin Endocrinol Metab 1985,60(5):848-854.
  • 10Milad MA,Ludwig EA,Lew KH,et al.The pharmacokinetics and pharmacodynamics of methylprednisolone in chronic re nal failure[J].Am J Ther 1994,1 (1):49-57.

共引文献72

同被引文献60

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部